TCL Archive FDA approval of two colon cancer therapies triggers discussion among researchers, clinicians about best treatment and clinical trial designs. CMS reimbursement pending; costs to U.S. of the new drugs could be billions per year, but some predict dramatic increases in survival. March 5, 2004
TCL Archive NCS Heeds Bloch’s Plea, To Consider Establishing Separate PDQ-Like System For General Public Use December 7, 1984
TCL Archive Mihich Subcommittee Recommendations For Augmenting Agents In BRMP Described December 7, 1979
TCL Archive Guest Editorial: Anil Potti Hires “Online Reputation Managers” As Journals Retract His Biomarker Research April 15, 2011
TCL Archive Tracor Lands Second Biggest NCI Contract-$6.6 Million To Manage Commercial Labs’ Portion Of Bioassay Program April 19, 1974
TCL Archive Phase III Trial Demonstrates Early Docetaxel Combined With ADT Can Extend Survival December 27, 2013
